Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are well established in clinical
practice for the treatment of type 2 diabetes, and are approved and recommended for weight …

Objective Little is known about the predictors of response to obesity interventions. Methods
In 450 participants with obesity, body composition, resting energy expenditure, satiety …

Background New obesity medications result in large weight losses. However, long-term
adherence in a real-world setting is challenging, and termination of obesity medication …

ABSTRACT Introduction: Healthcare providers (HCPs) see many patients with obesity-
related complications and are therefore well placed to help treat obesity itself. However …

Obesity treatment requires a chronic state of negative energy balance. Obesity medications
can help with this, increasing long‐term dietary compliance by promoting satiety or reducing …

Objective The study's objective was to examine the percentage of patients with an initial
antiobesity medication (AOM) fill who were persistent with AOM at 3, 6, and 12 months and …

Introduction: Data from randomized controlled trials show that liraglutide 3.0 mg, in
combination with diet and exercise, is associated with greater weight loss than diet and …

Aim To identify the sociodemographic, clinical and laboratory determinants relating to
patient adherence to liraglutide treatment among individuals with overweight or obesity …

La psoriasis (PsO) y la hidradenitis supurativa (HS) se asocian frecuentemente con la
obesidad. La inflamación crónica de bajo grado subyace a estas condiciones, por lo que si …

Recent publicity around the use of new antiobesity medications (AOMs) has focused the
attention of patients and healthcare providers on the role of pharmacotherapy in the …